The estimated Net Worth of Isaac Braun is at least $636 millier dollars as of 8 April 2019. Mr. Braun owns over 50,000 units of Pluri Inc stock worth over $636,208 and over the last 17 years he sold PSTI stock worth over $0. In addition, he makes $0 as Independent Director at Pluri Inc.
Isaac has made over 1 trades of the Pluri Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 50,000 units of PSTI stock worth $35,000 on 8 April 2019.
The largest trade he's ever made was buying 50,000 units of Pluri Inc stock on 8 April 2019 worth over $35,000. On average, Isaac trades about 2,500 units every 0 days since 2007. As of 8 April 2019 he still owns at least 636,208 units of Pluri Inc stock.
You can see the complete history of Mr. Braun stock trades at the bottom of the page.
Isaac Braun serves as Independent Director of the Company. Mr. Braun is a business veteran with entrepreneurial, industrial and manufacturing experience. He has co-founded and served as a board member of several high-tech start-ups in the areas of e-commerce, security, messaging, search engines and biotechnology. Mr. Braun is involved with advising private companies in the areas of capital raising and business development.
Isaac Braun is 67, he's been the Independent Director of Pluri Inc since 2014. There are 1 older and 5 younger executives at Pluri Inc. The oldest executive at Pluri Inc is Mark Germain, 69, who is the Independent Director.
Isaac's mailing address filed with the SEC is MATAM PARK, BUILDING #5, , HAIFA, L3, 3508409.
Over the last 17 years, insiders at Pluri Inc have traded over $7,081,854 worth of Pluri Inc stock and bought 2,345,914 units worth $14,327,834 . The most active insiders traders include Wolf Capital Limited Part..., Zami Aberman et Israel Ben Yoram. On average, Pluri Inc executives and independent directors trade stock every 64 days with the average trade being worth of $54,123. The most recent stock trade was executed by Zami Aberman on 10 February 2022, trading 80,616 units of PSTI stock currently worth $145,109.
Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late-stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off- the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a
Pluri Inc executives and other stock owners filed with the SEC include: